HCV patients had better outcomes on sofosbuvir-based treatment without interferon

HCV patients had better outcomes on sofosbuvir-based treatment without interferon
August 4, 2014

Patient-reported outcomes and work productivity were more negatively affected by hepatitis C treatment regimens that included pegylated interferon compared with interferon-free regimens, according to recent study data.

Zobair Younossi, MD, of the Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Virginia, and colleagues evaluated the patient-reported outcomes (PROs) obtained from questionnaires completed during two recent phase 3 clinical trials of sofosbuvir-based treatments with and without interferon. The FUSION study included 201 patients infected with HCV who received sofosbuvir and ribavirin for 12 or 16 weeks. The NEUTRINO study included 327 patients infected with HCV who received sofosbuvir and ribavirin plus interferon for 12 weeks.

Full Story »

Daclatasvir plus asunaprevir

HALLMARK, COSMOS: New HCV regimens show high cure rates

Novel direct-acting antiviral agents were effective in treating infection with hepatitis C virus genotype 1 — even in the hardest-to-treat patients — according to results from two major clinical trials published in the Lancet. 

Full Story....